Loading clinical trials...
Loading clinical trials...
A Phase I Study of the Safety, Tolerability, Pharmacokinetics Profiles and Preliminary Efficacy of 3D185 Monotherapy in Subjects With Advanced Solid Tumors
Conditions
Interventions
Highly selective FGFR1-3 inhibitor
Locations
2
United States
Sarcoma Oncolog Research Center
Santa Monica, California, United States
Shanghai East Hospital
Shanghai, China
Start Date
September 1, 2019
Primary Completion Date
December 30, 2025
Completion Date
December 30, 2026
Last Updated
May 29, 2025
NCT06625775
NCT05223608
NCT06051695
NCT06265727
NCT04665206
NCT05036226
Lead Sponsor
3D Medicines (Beijing) Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions